Tuesday, April 20, 2021 Daily Archives

Oxford Biomedica working to optimize vector production platform

by

Oxford Biomedica is optimizing its vector production system to boost yields and accelerate production in response to growing demand. The UK gene and gene therapy firm and contract development and manufacturing organization (CDMO) talked about efforts to improve its vector production platform last week during its Q4 presentation. The main aim – according to chief scientific officer Kyri Mitrophanous – is to increase viral vector production capacity and remain competitive. “We continue to invest in the lentiviral vector platform in…

April 20, 2021

Fareva to grow its newly acquired biomanufacturing capabilities

by

Fareva will make a “major investment†within its newly formed GTP Biologics division a year after entering the biologics CDMO sector. Fareva, a prominent third-party manufacturer in the small molecule active pharmaceutical ingredient (API) and finished formulation space, entered the biologics sector last year through the acquisition of two facilities from fellow French firm Pierre Fabre. Along with an oncology injectable plant in Pau, southwestern France, the firm picked up a monoclonal antibody (mAb) production facility in Saint-Julien-en-Genevois, on the…

April 20, 2021

Emergent issues: FDA orders production halt at Bayview plant

by

COVID-19 vaccine contract manufacturer Emergent BioSolutions has stopped production at its beleaguered Bayview, Maryland plant following a US FDA inspection that led to a Form 483 with nine observations. The US Food and Drug Administration (FDA) began an inspection at the Bayview site in Baltimore, Maryland on April 12 and, according to Emergent, four days later requested a manufacturing hold. “On April 16, 2021, at the request of the FDA, Emergent agreed not to initiate the manufacturing of any new…

April 20, 2021